NAGE
NEUTRAL
$4.69
Live
Niagen Bioscience, Inc. · NASDAQ
Target $13.6
(+190.0%)
$4.16
52W Range
$14.69
At a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Confidence
85%
NAGE demonstrates strong operational health with a Piotroski F-Score of 7/9 and a pristine balance sheet characterized by a very low Debt/Equity ratio (0.04). However, the stock is trading at a significant premium to its Graham Number ($2.08) and Intrinsic Value ($1.40), suggesting a valuation disconnect. While the company has successfully transitioned from historical losses to profitability—a rarity in the biotech sector—recent YoY earnings growth has plummeted by 41.6%. The conflict between a 'Strong Buy' analyst consensus and a completely bearish technical trend (0/100) warrants a cautious approach.
Key Strengths
Strong Piotroski F-Score (7/9) indicating robust financial health
Exceptional liquidity with a Current Ratio of 4.86
Negligible debt levels (Debt/Equity of 0.04)
Positive profitability (13.43% Profit Margin) compared to sector average (-12.38%)
Consistent track record of beating earnings estimates over the last 4 quarters
Key Risks
Sharp decline in YoY and Q/Q earnings growth (-41.6% and -42.4%)
Current price ($4.69) is more than double the Graham Number ($2.08)
Strongly bearish technical trend (0/100)
Significant price depreciation over the last 6 months (-37.2%)
High Price/Book ratio (4.90) relative to intrinsic value
AI Fair Value Estimate
Based on comprehensive analysis
$3.25
-30.7% below current price
Performance Snowflake
Multi-dimensional AI analysis across 5 key categories
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Historical Performance Trends
Long-term financial metrics and growth patterns
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability, Growth & Financial Health
Detailed profit margins, ROE, debt ratios, and liquidity metrics
Sector Comparison & Peer Analysis
Compare NAGE against industry averages and similar companies
Insider Trading & Analyst Ratings
Track insider transactions and Wall Street analyst recommendations
Past News Coverage
Recent headlines mentioning NAGE from our newsroom.
Newest → oldest
No matching news yet.